Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could low testosterone raise heart risk after spinal cord injury?

NCT ID NCT07227740

Knowledge-focused Sponsor: Craig Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at why men with spinal cord injury often have low testosterone and how that might damage blood vessels, raising the risk of heart attacks and strokes. Researchers will test blood vessel function in 48 men with recent spinal cord injury and low testosterone. They hope to uncover the link between testosterone deficiency and blood vessel health, which could lead to new ways to prevent heart disease in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vasoactive agents (acetylcholine, isoproterenol, sodium nitroprusside) infused into the arm artery
What this could lead to
If successful, this could point toward testosterone-based treatments to lower heart attack and stroke risk in men with spinal cord injury.
What could go wrong
This is an early, small observational study (48 participants) that measures biological markers, not clinical outcomes. It may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Only male participants of all races and ethnic backgrounds aged 18-89 with a history of motor complete (AIS A/B) paraplegia (NLI T3 or Below). Time since injury \<6 months at time of enrollment and diagnosed with normal and low T (Testosterone Deficiency defined as \< 300ng/dL)

Ages

18 to 89 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between ages 18-89 years of age * Male Sex * History of motor complete (AIS A/B) paraplegia (NLI T3 or Below) * Time since injury \<6 months at time of enrollment (Subacute injury) * Testosterone Deficiency defined as \< 300ng/dL Exclusion Criteria: * Overt cardiovascular disease assessed by a) medical history, b) physical examination c) electrocardiogram * Anaphylaxis to betadine, lidocaine, iodine * Active infection at time of enrollment. * Recent surgery (\<1 month) at time of enrollment. * History smoking tobacco (currently or in the past 12 months) * History of more than low-risk history of alcohol consumption * History of drug abuse * History of use of cardiovascular-acting (i.e. statins, beta-blockers) therapeutics * History of other health habits, medications, and supplements that could influence the outcome measures deemed by principal investigators and investigative team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endothelial dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aneurysm hypogonadism hypogonadism, male spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endothelial dysfunction Spinal cord injuries Testosterone deficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Craig Hospital

    RECRUITING

    Englewood, Colorado, 80113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.